- Home
- LYRA vs BIAF Comparison
LYRA vs BIAF Comparison
Compare LYRA & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- BIAF
- Stock Information
- Founded
- LYRA 2005
- BIAF 2014
- Country
- LYRA United States
- BIAF United States
- Employees
- LYRA N/A
- BIAF N/A
- Industry
- LYRA Medical/Dental Instruments
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LYRA Health Care
- BIAF Health Care
- Exchange
- LYRA Nasdaq
- BIAF Nasdaq
- Market Cap
- LYRA 6.1M
- BIAF 12.2M
- IPO Year
- LYRA 2020
- BIAF 2022
- Fundamental
- Price
- LYRA $0.10
- BIAF $0.47
- Analyst Decision
- LYRA Hold
- BIAF Hold
- Analyst Count
- LYRA 4
- BIAF 1
- Target Price
- LYRA $1.25
- BIAF N/A
- AVG Volume (30 Days)
- LYRA 1.8M
- BIAF 28.5M
- Earning Date
- LYRA 05-06-2025
- BIAF 05-14-2025
- Dividend Yield
- LYRA N/A
- BIAF N/A
- EPS Growth
- LYRA N/A
- BIAF N/A
- EPS
- LYRA N/A
- BIAF N/A
- Revenue
- LYRA $1,534,000.00
- BIAF $9,362,022.00
- Revenue This Year
- LYRA N/A
- BIAF N/A
- Revenue Next Year
- LYRA $237.15
- BIAF $19.99
- P/E Ratio
- LYRA N/A
- BIAF N/A
- Revenue Growth
- LYRA N/A
- BIAF 269.68
- 52 Week Low
- LYRA $0.08
- BIAF $0.24
- 52 Week High
- LYRA $5.65
- BIAF $3.16
- Technical
- Relative Strength Index (RSI)
- LYRA 39.49
- BIAF 46.68
- Support Level
- LYRA $0.08
- BIAF $0.46
- Resistance Level
- LYRA $0.10
- BIAF $0.54
- Average True Range (ATR)
- LYRA 0.01
- BIAF 0.08
- MACD
- LYRA 0.00
- BIAF -0.01
- Stochastic Oscillator
- LYRA 47.78
- BIAF 5.04
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.